Hemostatic agents are medical devices that are utilized to control bleeding during surgical procedures. Advancements in hemostasis technology has led to development of wide range of products that have enabled clinicians to provide proper emergency assistance to patients. Hemostatic products include thrombin sealants, fibrin glue, bovine serum/albumin/glutaraldehyde, gelatin matrix, microfibrillar collagen matrix, and oxidized regenerated cellulose. Each of these agents differ in mechanism, application, and cost. Active hemostatic agents act physiologically by countering with blood coagulation cascade and lead to faster hemostasis.
According to the data by the Centers for Disease Control and Prevention (CDC), the prevalence rate of hemophilia in the U. S. is 1 in every 5000 male births. Von Willebrand disease (VWD), another bleeding disorder, is the most commonly occurring blood disorder that affects 1% of the population of the U.S. 1 in every 100 (almost 3.2 million) people in the U.S. is suffering from Von Willebrand disease (VWD). High number of patients with bleeding disorders increase the need for advanced hemostasis products. The patient pool with different chronic diseases is also growing rapidly across the world. This is likely to increase the number of surgical procedures, consequently propelling the active hemostasis market in the near future. Strict but inconsistent regulatory policies across the world are creating apprehensive environment among the market players, thereby restraining market growth of active hemostatic agents market. Increase in global trauma and accident cases is another driver of the active hemostasis agents market. According to the World Health Organization (WHO), an estimated 1.25 million people are killed in road traffic accidents worldwide every year. Globally, hemorrhage or excessive bleeding is responsible for over one third of pre-hospital deaths and over 40% of deaths within the first 24 hours. Moreover, a study conducted by the U.S. Armed Forces suggested that 25% of battle field fatalities are medically preventable. Nearly 90% of these deaths are due to uncontrolled blood loss. Such high number of deaths has urged governments to develop and provide better hemorrhage control systems.
Active hemostatic agents market has been segmented by type of products, end users and geography. On the basis of product type, the global active hemostatic agents market can be segmented into thrombin based hemostats, surgical sealants, combination products, etc. On the basis of end users type, the global active hemostatic agents market can be segmented into hospitals, ambulatory surgical centers, and specialty clinics, etc.
Depending on geographic segmentation the global active hemostatic agents market is segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America and Europe expected continue to dominate the active hemostatic agents market due to high number of surgeries carried out in these regions. According to Eurostat, nearly 1.35 million caesarean sections were performed in the region in 2013. Moreover, the steep growth in other surgical procedures such as laparoscopy, knee and/or hip replacement surgeries, hernia operations, and growing demand for minimally invasive procedures offering less pain and faster recovery has propelled the use of hemostats by hospitals and clinics. Asia Pacific is considered the most lucrative market and is anticipated to grow at the highest growth rate during the forecast period. Growth of the active hemostatic agents market in Asia is attributed to strong economic growth, increase in disposable income, rise in health care infrastructure, and the growing investments by active hemostatic agents market players in this region.
Market for active hemostasis agents highly organized, with the few players accounting for major share of the total market revenue. The key players involved in global active hemostatic agents market includes Medtronic Plc., Ethicon Inc. (part of Johnson & Johnson Company), Pfizer Inc., Baxter International Inc., CryoLife, Inc., Integra Life Sciences Corporation, etc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.